SK Biopharm has created a new drug development task force (TF) with SK Corporation.

Reporter Kim Jisun / approved : 2023-03-27 03:15:25
  • -
  • +
  • 인쇄
This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology
사진= 연합뉴스 제공 

 

[Alpha Biz=(Chicago) Reporter Kim Jisun] SK biopharmaceuticals has created a new drug development task force (TF) with SK Corporation, the holding company of SK Group. 

 

With a large number of key figures from SK and SK Biopharm in the TF, Choi Yoon-jung, head of SK biopharmaceuticals' strategic investment team, the eldest daughter of SK Group Chairman Choi Tae-won, reportedly joined the group.

According to the industry on the 24th, the two companies have recently set up such a TF to strengthen the development of new drugs in the pharmaceutical and bio sectors. However, as it is still in the early stages of TF formation, no specific development direction has been decided.

While SK CEO and Vice Chairman Jang Dong-hyun headed the TF, SK joined Kim Yeon-tae, head of the bio-investment center, and Cho Ah-ryeon, head of the bio-investment center group, while Lee Dong-hoon and Yoo Chang-ho, head of the strategic and investment division, joined SK biopharmaceuticals. On top of that, Choi's eldest daughter, Choi, is also known to participate.

TF plans to start work on the 27th.

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

[Exclusive] Samsung Electronics Passes NVIDIA’s HBM3E 12-High Qualification Test, Secures Supply Deal2025.09.19
Civic Groups File Complaint Against Baemin and Coupang Eats Over Alleged Misleading “One-Person Free Delivery” Promotions2025.09.19
KT Confirms Additional Victims in Unauthorized Micro-Payment Case, Faces Criticism Over Initial Response2025.09.19
KFTC Grants Conditional Approval for Joint Venture Between Shinsegae Group and Alibaba Group2025.09.19
Supreme Court Rules in Favor of NTS on U.S. Unregistered Patent Royalties2025.09.19
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사